Skip to content

Tomorrow's Pharma Control Tower Is Vastly Different From Today's, And Today's Is Just Getting Started

Picture of Ilya Preston
Tomorrow's Pharma Control Tower Is Vastly Different From Today's, And Today's Is Just Getting Started
12:47

 

PAXAFE - BLOG BANNER - Tomorrows Pharma Control Tower_ New

 

Since 2019, PAXAFE has led the strategic vision and thought leadership around best-in-class life sciences control towers.

You can follow the evolution through my own words:

(For the fuller evaluation framework behind that last point, see our guide to pharmaceutical control towers.)

 

PAXAFE's GxP quality compliance and logistics orchestration platform supports some of the biggest names in pharma, biotech, logistics, packaging, and IoT. At its core, this vision is what got us here.

But I want to be clear: the control tower of today is NOT the control tower of tomorrow.

And once again, PAXAFE is forging the path toward the control tower of tomorrow. Here are five things PAXAFE has built TODAY to get customers ready for the use case of TOMORROW:

 

1. Handling unit tracking, not just device tracking

PAXAFE Handling Units on Screen

 

Okay, I have to admit — this first one is a bit of a cheat code. This is something PAXAFE already supports today, but it's a recent development from 2026.

Most visibility control towers’ tracking is basic. Track a device ID. Track a product ID. Track a shipment ID, a container ID. One device per shipment record. No mixed real-time and conventional devices on a single shipment. No split shipment support — and forget batch traceability.

PAXAFE tracks by handling unit, exactly how life sciences leaders do: pallet ID, box ID, with product, packaging, batch, material code, dosage, serialization, and expiry to follow.

Up to 100 devices per single shipment record (good luck processing all of that buffer data). Real-time and conventional. Split shipment support, full product release, and full end-to-end product and batch lineage through manufacturing, warehousing, and in-transit logistics — the same device-agnostic visibility we've built Command Center around from day one.

 

2. The platform disappears into how you already work

The UI and the platform will become optional. Tomorrow's control tower will be embedded into your exact way of working. It will be your email, your Teams, your Slack — everything powered by PAXAFE.

The irony is that you can't jump to tomorrow's control tower without building the full processing and normalization layers, integration layer, and other core functionality that make today's platform great. You need to crawl and walk today to run tomorrow. Customers who become proficient in understanding the inner workings of the platform will gain the greatest benefit from tomorrow's version.

 

3. GxP and CSV are about to flip

Validation in GxP software has traditionally been a paperwork exercise: a binder of scripted tests assembled after the software was already built, repeated wholesale every time something changed. At PAXAFE we’re taking a different path, one aligned with FDA’s Computer Software Assurance (CSA) guidance, GAMP 5, and Annex 11. Assurance should be proportionate to risk and should live inside the software lifecycle, not trail behind it. Every GxP-relevant requirement in CONTXT carries a risk assessment tied to its intended use, and the depth of testing scales accordingly. Functions that touch regulated release decisions get rigorous scripted qualification with full traceability, while lower-risk areas get leaner scenario-based verification. Less burdensome evidence where risk is low, never no evidence.

What makes this work is that we’ve built qualification directly into our delivery pipeline. Automated tests execute against each acceptance criterion and produce complete, traceable evidence (who ran what, when, what was actually observed, pass or fail) as a byproduct of delivery rather than a separate documentation project. Just as importantly, we’re clear about what the automation doesn’t do. A green pipeline is not a validated state, and final acceptance of every qualification package remains a controlled human quality decision. CSA in the pipeline, CSV in the record: the machines run the tests, and Quality owns the validated state.

 

4. Silos will continue to disappear

Today, there are silos everywhere. One platform or home-grown project geared toward tracking TIR/TOR in manufacturing. Many WMS and ERP systems. Tons of visibility tools from IoT devices, packaging providers, and carriers. QMS with product stability data and SOPs. Raw material and API lanes. Manufacturing. Distribution. Last mile. This platform for cold chain. This platform for tracking. This process for quality release. Everything disconnected, everything has its own "thing."

PAXAFE has made great strides in showing how all of the above can be consolidated — from siloed point solutions where decisions and data don't flow through, into one unified system of record. That's the same argument behind real cold chain data consolidation: the fix was never another point tool, it's reconciling the record.

 

5. Control towers will become verticalized and specialized

Think about the visibility control towers of the last decade, as well as the broader supply chain orchestration platforms that have been around for decades. All of these tools, yet pharma sees more loss, inefficiency, and decision paralysis than ever.

Generic is adequate for commodities and retail. Generic cannot meet the needs of a pharma logistics control tower operating under GxP. And the pharma industry has a lot of tech debt scar tissue to show for it.

Going broad before going deep was a fad to raise a ton of money in the era of the software boom. Today, it's a recipe for churn and disaster.

AI as a bolt-on doesn't work. GxP as an add-on to an existing SDLC and an established infrastructure with tens of millions of lines of code doesn't work. These two things are either built into your DNA from the ground up, or they don't work. That's why expanding from life sciences into commodities may be possible. Expanding from commodities into life sciences is not.

Tomorrow's control towers will be AI-native and will have GxP in their DNA before they turn one year old.

Today's established control towers will bow out of life sciences, or invest heavily to hyper-specialize — realizing that the upside potential of solving the most difficult problem in logistics, the cold chain problem, unlocks the privilege of solving some of the most interesting problems in supply chain. We go deeper on what that specialization actually requires — end to end, from lane qualification through automated product release — in the rest of our blog.

 

 

About PAXAFE

PAXAFE is a GxP decision intelligence platform that strives to put the cold chain on autopilot.

Acting as the system of record for every time, temperature and value sensitive shipment and batch, PAXAFE works with cold chain manufactures and service providers to eliminate silos, ensures compliance, and empower teams with contextual intelligence to drive towards zero waste.

 

FAQ

What makes a control tower "pharma-grade" instead of just a generic logistics control tower?

A pharma-grade control tower is built around GxP from the ground up — handling unit-level traceability (pallet, box, batch, serialization), device- and carrier-agnostic ingestion, lane qualification tied to SOPs, and GxP-validated product release. Generic supply chain control towers are built for commodity visibility and bolt compliance on afterward, which is why they struggle to meet regulated pharma requirements. For a full evaluation framework, see our guide to pharmaceutical control towers.

What is the difference between supply chain visibility and supply chain orchestration?

Visibility tells you where a shipment is and what its temperature was. Orchestration goes further — it connects that data to a decision, like whether a lane still qualifies, whether a shipment is on track for automated release, or whether a workflow should trigger automatically. A control tower that only offers visibility still requires a human to manually decide what to do with the information; an orchestration layer acts on it.

What is Computer Software Assurance (CSA), and how is it different from Computer System Validation (CSV)?

CSA is the FDA's risk-based approach to validating production and quality system software, finalized in 2025 and updated in February 2026. Unlike traditional CSV, which applies the same exhaustive scripted testing to every system regardless of risk, CSA scales validation effort to actual patient-safety and product-quality risk, and explicitly accounts for AI/ML systems and cloud-based software — a better fit for platforms that update continuously rather than once a year.

Why can’t AI or GxP be "bolted on" to an existing control tower platform?

Because both require decisions made at the architecture level, not the feature level: how data is structured, how validation is scoped, how audit trails are generated. Retrofitting AI onto a platform not built for it means the AI can't be grounded in real SOPs and lane history. Retrofitting GxP onto a platform not built for it means validation becomes a slow, manual exercise layered on top of code that wasn't designed to be audited. Both have to be present in the system's DNA from the start.